Brokerages Set Glaukos Co. (NYSE:GKOS) Price Target at $135.45

Glaukos Co. (NYSE:GKOS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven research firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $135.45.

Several research firms recently issued reports on GKOS. Wells Fargo & Company increased their target price on Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a research note on Monday, October 21st. Truist Financial upped their target price on shares of Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. BTIG Research raised their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. upped their price objective on Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th.

Glaukos Trading Up 0.7 %

Shares of NYSE GKOS traded up $0.96 during mid-day trading on Friday, reaching $143.65. 165,871 shares of the company's stock were exchanged, compared to its average volume of 570,121. The company's 50-day moving average is $134.13 and its 200-day moving average is $124.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market capitalization of $7.92 billion, a price-to-earnings ratio of -47.62 and a beta of 1.02. Glaukos has a 52-week low of $59.58 and a 52-week high of $146.86.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos's revenue was up 23.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.50) earnings per share. Analysts expect that Glaukos will post -1.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Joseph E. Gilliam sold 2,275 shares of the company's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cetera Advisors LLC acquired a new stake in shares of Glaukos in the 1st quarter worth $213,000. GAMMA Investing LLC boosted its holdings in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock valued at $141,000 after purchasing an additional 486 shares in the last quarter. LVW Advisors LLC acquired a new position in Glaukos during the 2nd quarter worth approximately $213,000. Sequoia Financial Advisors LLC acquired a new position in Glaukos during the 2nd quarter worth approximately $229,000. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Glaukos during the 2nd quarter worth approximately $6,832,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.